Neuroblastomas Vulnerable To Novel Class Of Drugs May Be Identified By Genetic Biomarker
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists reported at the annual meeting of the American Association for Cancer Research in Washington, April 6-10. The findings (abstract 4622) were discussed in a minisymposium. The work was published in Cancer Discovery, a journal of the American Association of Cancer Research...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Children | Genetics | Health | Hospitals | Neuroblastoma | Neurology